a University College of Pharmacy, University of Punjab , Lahore , Pakistan.
b National Institute of Lasers and Optronics , Pakistan Atomic Energy Commission , Islamabad , Pakistan.
J Drug Target. 2018 Apr;26(4):296-310. doi: 10.1080/1061186X.2017.1380655. Epub 2017 Sep 28.
Doxorubicin (DOX) is the most effective chemotherapeutic drug developed against broad range of cancers such as solid tumours, transplantable leukemias and lymphomas. Conventional DOX-induced cardiotoxicity has limited its use. FDA approved drugs i.e. non-pegylated liposomal (Myocet) and pegylated liposomal (Doxil) formulations have no doubt shown comparatively reduced cardiotoxicity, but has raised new toxicity issues. The entrapment of DOX in biocompatible, biodegradable and safe nano delivery systems can prevent its degradation in circulation minimising its toxicity with increased half-life, enhanced pharmacokinetic profile leading to improved patient compliance. In addition, nano delivery systems can actively and passively target the tumour resulting increase in therapeutic index and decreased side effects of drug. Foreseeing the need of a comprehensive review on DOX nanoformulations, in this article we for the first time have given an updated insight on DOX nano delivery systems.
阿霉素（DOX）是针对广泛的癌症（如实体瘤、可移植性白血病和淋巴瘤）开发的最有效的化疗药物。传统的 DOX 诱导的心脏毒性限制了其应用。美国食品和药物管理局批准的药物，即非聚乙二醇化脂质体（Myocet）和聚乙二醇化脂质体（Doxil）制剂，无疑显示出相对较低的心脏毒性，但也带来了新的毒性问题。将 DOX 包封在生物相容性、可生物降解和安全的纳米递药系统中，可以防止其在循环中降解，最大限度地减少其毒性，延长半衰期，增强药代动力学特征，从而提高患者的顺应性。此外，纳米递药系统可以主动和被动靶向肿瘤，从而提高治疗指数，降低药物的副作用。鉴于对 DOX 纳米制剂进行全面综述的需要，本文首次对 DOX 纳米递药系统进行了更新的深入了解。
